CellZome AG Company Profile

News Articles [ 10 Associated News Articles listed on BioPortfolio]

Cellzome Achieves Clinical Candidate Milestone from Inflammation Alliance with GlaxoSmithKline

Cellzome’s KinobeadsTM platform drives design of selective clinical candidate and lead for additional kinase target Cambridge, United Kingdom and Heidelberg, Germany, 14th September 2011...

Cellzome Announces Achievement of Second Milestone in Epigenetics Collaboration with GSK

Heidelberg, Germany and Cambridge, UK- 8th February 2011 – Cellzome announced today that it has achieved the second milestone in its epigenetics alliance with GlaxoSmithKline. The milestone...

Cellzome to Study Epigenetic Factors with Neusentis

Heidelberg, Germany – 10 May 2011 – Cellzome announced today a joint project with Pfizer’s Pain & Sensory Disorders and Regenerative Medicine unit ‘Neusentis’, t...

Proteomic Study Published in the Journal Nature Paves the Way for New Treatment for Incurable Leukaemia Using an Epigenetic Inhibitor

Heidelberg, Germany, 2nd October 2011 – A study published in Nature online today (Dawson et. al. Advanced online Publication, DOI: 10.1038/nature10509) by Cellzome and others has identified th...

Sale-zome

Ebb & Flow Sale-zome VCs will barely make a return on their investment in German proteomics play Cellzome AG, which is being acquired by long-time partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). GSK...

Cellzome Builds Scientific Advisory Board with World-Leading Experts in Proteomics, Epigenetics and Immunology

Heidelberg, Germany, Cambridge, UK 23rd February 2011 – Cellzome announces the appointment of four new members to its Scientific Advisory Board (SAB), further extending its scientific netwo...

Getting selective for gamma

Cellzome and Exelixis have independently designed the first highly selective inhibitors of the gamma-isoform of PI3K. Exelixis hopes to out-license its inhibitors, whereas the recent acquisition of Ce...

Cellzome Founder wins EU Women Innovators Award - Dr. Gitte Neubauer awarded first prize for the foundation of Cellzome

Heidelberg, Germany, 6th December 2011 – Cellzome announces today that Dr. Gitte Neubauer, one of the scientific founders of Cellzome, has received the highly esteemed EU Women Innovators A...

Drugs and Medications [0 Results]

None

PubMed Articles [ 6 Associated PubMed Articles listed on BioPortfolio]

Discovery of novel PI3Kγ/δ inhibitors as potential agents for inflammation.

Dual PI3Kγ/δ inhibitors have recently been shown to be suitable targets for inflammatory and respiratory diseases. In a recent study we described the discovery of selective PI3Kγ inhibitors based o...

Discovery of 5-(2-amino-1,2,4triazolo1,5-apyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.

Herein, we disclose the discovery of a series of 7-substituted triazolopyridines which culminated in the identification of 14 (CZC24758), a potent, orally bioavailable small-molecule inhibitor of PI3K...

Chronic treatment with a novel γ-secretase modulator, JNJ-40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease.

Background and purpose: γ-Secretase modulators (GSMs) represent a promising therapeutic approach for Alzheimer's disease (AD) because they selectively decrease amyloid ß 42 (Aß42), a particularly n...

SAR studies around a series of triazolopyridines as potent and selective PI3Kγ inhibitors.

Herein we describe the SAR of a novel series of 6-aryl-2-amino-triazolopyridines as potent and selective PI3Kγ inhibitors. The 6-aryl-triazolopyridine core was identified by chemoproteomic screening...

H-score, a mass accuracy driven rescoring approach for improved Peptide identification in modification rich samples.

Currently, scoring algorithms of many popular search engines for tandem mass spectrometry (MS/MS) data only partially utilize the information content of high mass accuracy MS/MS data. We have develope...

Clinical Trials [0 Results]

None

Companies [ 3 Associated Companies listed on BioPortfolio]

Cellzome

Cellzome is a privately-owned drug discovery and development company, and a leader in the use of chemical proteomics technologies to identify a new generation of drug candidates for the treatment...

CellZome AG

Cellzome is a privately-owned drug discovery company identifying a new generation of kinase- targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeutics is driven by Kin...

Cellzome Inc.

Cellzome is a privately-owned drug discovery and development company identifying a new generation of kinase-targeted drugs to treat inflammatory diseases. Its pipeline of small-molecule therapeuti...